SCHEMBL264373

SCHEMBL264373

C[C@@H](NC(=O)c1ccc2nc(C(C)(O)C(F)(F)F)ccc2c1)c1ccnc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.46
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
TRPM8 Q7Z2W7 4/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HDAC3 O15379 1/20 0.37
CYP2C9 P11712 1/20 0.37
HDAC1 Q13547 1/20 0.37
PLK1 P53350 1/20 0.37
RET P07949 1/20 0.37
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
GAA P10253 2/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264363 0.93 PPARG (0.46) PPARGLMNAMEN1MAPK1KMT2A
SCHEMBL262685 0.93 PPARG (0.46) PPARGLMNAMEN1MAPK1KMT2A
SCHEMBL264576 0.88 PPARG (0.47) PPARGLMNAMEN1MAPK1KMT2A
SCHEMBL263915 0.81 TRPM8 (0.39) PPARGLMNAMEN1MAPK1KMT2A
SCHEMBL265243 0.81 TRPM8 (0.39) PPARGTAS1R3TAS1R1TRPM8PLK1
SCHEMBL14147967 0.77 PPARG (0.44) PPARGTRPM8
SCHEMBL263527 0.77 TAS1R3 (0.37) PPARGMEN1KMT2ATAS1R3TAS1R1
SCHEMBL1838653 0.77 BRPF1 (0.51) LMNAMEN1KMT2ACYP2C9ALDH1A1
SCHEMBL1841353 0.77 BRPF1 (0.51) LMNAMEN1KMT2ACYP2C9ALDH1A1
SCHEMBL264499 0.76 HPGDS (0.44) PPARGLMNAMEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS OPRL1, CNR1, TRPV1 PPARG 771/4885LMNA 2567/4885MEN1 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.